A detailed history of Citigroup Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Citigroup Inc holds 65,956 shares of RCUS stock, worth $1.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,956
Previous 47,653 38.41%
Holding current value
$1.04 Million
Previous $725,000 39.03%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$13.69 - $18.01 $250,568 - $329,637
18,303 Added 38.41%
65,956 $1.01 Million
Q2 2024

Aug 12, 2024

SELL
$14.59 - $18.48 $3.92 Million - $4.96 Million
-268,474 Reduced 84.93%
47,653 $725,000
Q1 2024

May 10, 2024

BUY
$14.83 - $20.18 $2.8 Million - $3.81 Million
188,896 Added 148.47%
316,127 $5.97 Million
Q4 2023

Feb 09, 2024

SELL
$13.43 - $19.63 $248,428 - $363,115
-18,498 Reduced 12.69%
127,231 $2.43 Million
Q3 2023

Nov 09, 2023

BUY
$17.62 - $23.54 $441,962 - $590,453
25,083 Added 20.79%
145,729 $2.62 Million
Q2 2023

Aug 10, 2023

SELL
$16.97 - $22.03 $3.92 Million - $5.1 Million
-231,290 Reduced 65.72%
120,646 $2.45 Million
Q1 2023

May 11, 2023

BUY
$15.96 - $23.15 $3.6 Million - $5.21 Million
225,255 Added 177.81%
351,936 $6.42 Million
Q4 2022

Feb 09, 2023

SELL
$19.7 - $35.71 $2.13 Million - $3.86 Million
-108,002 Reduced 46.02%
126,681 $2.62 Million
Q3 2022

Nov 10, 2022

BUY
$23.23 - $30.07 $1.31 Million - $1.69 Million
56,183 Added 31.48%
234,683 $6.14 Million
Q2 2022

Aug 10, 2022

BUY
$17.23 - $37.73 $2.51 Million - $5.5 Million
145,896 Added 447.48%
178,500 $4.52 Million
Q1 2022

May 12, 2022

SELL
$28.92 - $41.83 $2.21 Million - $3.19 Million
-76,296 Reduced 70.06%
32,604 $1.03 Million
Q4 2021

Feb 10, 2022

BUY
$31.38 - $48.47 $1.46 Million - $2.25 Million
46,415 Added 74.28%
108,900 $4.41 Million
Q3 2021

Nov 10, 2021

BUY
$26.93 - $37.68 $1.68 Million - $2.35 Million
62,485 New
62,485 $2.18 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.13B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.